Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$HQGE .0005 Pay attention to this one
Right now it's way under the radar because of the focus on COVID-19 stocks but once the air clears, this will get some great attention imo
Very nice merger news announced yesterday with a company doing $3 million in annual sales (see links)
Within minutes after the news came out, filings hit to go current showing only $485k in liabilities and $5.1 million in hard assets, that's $4.5 million in positive shareholder equity on top of a killer merger coming in
https://www.otcmarkets.com/stock/HQGE/news/HQ-Global-Education-Inc-Acquires-1oneninety5-LLC?id=256228
https://www.zoominfo.com/c/1oneninety5/399122274
The TA updated the s/s on March 6th with unrestricted shares barely over a billion, shares held at the DTC are just over 800m, and last float was at 32m about 9 months ago
Even though the o/s is high, 85% of the commons are held tightly by management
The company has a ZERO r/s history, never touched .0001 (52 wk low .0002), and the highest volume day ever was only 83 million shares
Definitely imo worth grabbing a few shares while it's in the trips. Great merging company, great chart, and great balance sheet!
ACB AEMD AIM ALL ALPP ANY ARYC AVXL AYTU BIG BIOC BMIX BVTK CAN CTYX DBMM DECN DIS ENZC ETC ETCG ETH ETHE EVARF FNHI FONU GBTC GFTX GME GNCP GRPS GRYN HEMP HIPH IGEX IMIMF IMO INO INQD IPIX KGKG KNOS KWBT LOW MCIG MILV NGTF NIO NOW NSRI NWBO OWCP PASO PBIO PCTL PMCB PPL PTOP PURA RCL RGDEF SBES SFOR SGMD SINT SMH SMME SNDD SRMX TLSA TXTM UBID UPZS VNUE VPLM VRUS VSTR WDRP WHEN WOGI XMET ZAAG ZYRX
Failed test for their drug. VBIV is a good buyout candidate
Damn, wtf happened to ACST?
Once in a while there's a ticker that jumps out at me as trading way out of it's realm of the 'norm'
This time $PLFF hit my radar.
First, it's a very dormant ticker. Charting its historic activity, it's never traded more than a couple hundred thousand shares (give or take a few) in any given trading session in the 9+ years it's been traded and those were few and far in between each other
But now in the last month those spikes have been getting closer with the last week or so hitting historic volume levels twice consisting of almost all buys on the ask and very few shares hitting the bid
The last volume surge last week was followed by some very hefty bids including a $15,000 offer at the top bid in the mid subs with Friday's close showing a few hundred grand share bids sitting at and above .01 with zero fills. That's the bid moving up 100% with big blocks and zero fills
Key takeaways for me indicating a run is coming are the sudden interest in the ticker, the TA is updating S/S daily, and the last Q reported positive equity with over $7m in assets
Safe for me to say, based on experience, this type of activity usually indicates the company may be bringing the ticker back up to date on filings or there may be some type of change in control about to happen
In any event, keep this one on close watch, it could get very explosive imo
Going into Monday UBID will be on a lot of radars.
Not much posting on iHub but decent twitter buzz.
I been in touch with IR and updates are due to hit this week
Confirmed still only 50m shares unrestricted with 47m share float
Also keep LTHO on top of your watchlist going into Monday. Hearing that CEO will finally come through this week with some kind of update pertaining to the $5-6m annual revenue Hemp manufacturer/retailer they're in negotiations with. Says deals are finally coming together
HENC was red hot Friday. I traded it from .004 to .015ish but thought it was done. Boomed to high .02's late afternoon. Debate going on now of where the $16m in asset property went and where are the proceeds. They definitely sold the assets in Oct. news and Sept 30th fins back it, question is where did the proceeds go. In any event, it should be a very nice ticker to trade until some kind of confirmation is released or materializes explaining where the money is from the oil asset sale.
Since you posted them...
ACST hit a 50% gain before forming a new support at 2.18'ish.
First pulled back on 23rd of Dec to 2.18 followed by nice volume and pps spike. Down back to 2.18 on Fri. on light volume/ that's the bullish double bottom. Watch for volume to increase again, lots of news out there saying the pullback is only temp.
VBIV just beasting. Up 100% and still going.
BABYF Pulling back a bit on light volume but the volume surge on the 19th is still holding at the higher pps levels. I do like the company, just 'F' tickers can be sneaky when converting. Up side is conversions are getting bought up near the 52wk high
Thanks Sobek. I think this company has a good future in this niche
BABYF Details -
PR's and Filings found at sedar.com
On October 28, 2019, the Company was granted a patent for its two products: (1) 100% plant-based toddler drink/formula which is scheduled to be launched in 2020, and (2) 100% plant-based infant formula, which is scheduled to be launched following FDA approval
a/o 9/30/2019
assets $5.497m
liabilities $527k
cash on hand $4.057m
O/S 67.139m a/o 12/23/19
Float 31.332 a/o 10/18/2019
On June 12, 2019, ASB completed a reverse take-over transaction with Else GH by way of a share exchange, which constituted ASB’s qualifying transaction (the “Transaction” or “RTO”). Upon the completion of the Transaction, ASB changed its name from ASB Capital Inc. to Else Nutrition Holdings Inc. In connection with the Transaction, Else GH became a wholly owned subsidiary of the Company
On November 12, 2019, the Company shares began trading on the OTCPK under the trading symbol ‘BABYF’.
PR From 12/19/19
NEWS RELEASE
Else Nutrition Holdings Inc. Engages The Sawtooth Group for Branding & Bolsters Advisory Board
VANCOUVER, British Columbia, December 19, 2019 - ELSE NUTRITION HOLDINGS INC. (TSX-V: BABY, OTCQB: BABYF) (“Else” or the “Company”), a developer of a real alternative to dairy-based infant nutrition, is pleased to announce the following updates to shareholders.
Key Highlights
? Else Nutrition has engaged an independent, full-service agency, The Sawtooth Group of Red Bank, New Jersey, for branding strategy and creative asset development. Sawtooth brings years of expertise specializing in the food and better-for-you brand sectors.
? The company signs Katie Kaswell, former VP of Marketing for Plum Organics baby food, as the latest addition to its Advisory Board. She brings extensive U.S.-focused infant nutrition experience, adding to Else Nutrition’s already infant nutrition expert team.
Branding & Strategic Marketing Agency Selected
Else Nutrition Holdings Inc. has engaged and commenced strategic brand development and creative work with The Sawtooth Group, an independent agency based in Red Bank, New Jersey. With an impressive client roster including McCormick, Finlandia, and Explore Cuisine, Sawtooth brings over 3 decades of progressive branding experience to the engagement. The Sawtooth Group holds years of progressive experience in food brands and better-for-you brands.
“Having a deeply seasoned food and consumer goods partner on board as part of our efforts is instrumental. They’ve proven their prowess helping various startups to scale impressively. They simply get today’s health-conscious consumer, and can help Else express its clean label offering to consumers. Their involvement will be catalytic as we launch and grow in the North American market,” remarked Hamutal Yitzhak, CEO and Co-Founder of Else Nutrition.
The work scope spans: branding strategy, brand visual identity, creation of brand assets including website development, digital and social media creatives.
President & CEO of The Sawtooth Group, Kristi Bridges stated, “We are beyond thrilled to be working with Else Nutrition to bring to life their mission to provide a plant-based baby nutrition to a wanting market. As an agency with a management team of mom’s with young children, who also have deep expertise in the health and wellness market, we believe parents deserve to have better choices when it comes to feeding their children and we’re excited to introduce them to Else.”
Former VP Marketing of Plum Organics Joins Else Advisory Board
Else Nutrition announces the addition of Katie Kaswell to the Advisory Board of Else Nutrition GH Ltd. With over 10 years of experience in the baby food category, Katie helped propel the Plum Organics brand from startup to leading player in the industry in the U.S. market, through its acquisition by Campbell Soup Company.
“Else’s mission to bring clean-label, plant-based alternatives to families, is much needed in the baby food category. As a mom myself, I was drawn to the Else team’s passion for helping families and their commitment to the highest quality products for little ones,” stated Katie Kaswell.
“We are extremely pleased to add Ms. Kaswell’s deep baby nutrition experience to our growing Advisory Board. Katie’s expertise will greatly benefit us, as she advises on branding and marketing elements. Her vast US.-focused baby nutrition expertise will complement the infant nutrition expertise of the existing team,” said Hamutal Yitzhak.
PR From 12/16/19
ELSE NUTRITION RECEIVES FAVORABLE REGULATORY ASSESSMENT AHEAD OF U.S. MARKET LAUNCH
VANCOUVER, British Columbia, December 16, 2019 (GLOBE NEWSWIRE) - ELSE NUTRITION HOLDINGS INC. (TSX-V: BABY, OTCQB: BABYF) (“Else” or the “Company”), a developer of plant-based alternatives to dairy-based baby nutrition, announces that it has received a favorable regulatory assessment of its toddler formula ingredients from EAS Consulting Group, LLC, which conducted a preliminary review of the Else formula in view of the FDA (Food and Drug Administration) requirements.
With vast, global expertise in regulatory approvals, and specialty in FDA requirements, EAS has unique experience and capability pertaining to the introduction of food, drinks and new infant formulas.
“The EAS Infant Formula Team has confirmed that Else toddler formula intended to be marketed in the U.S. meets the regulatory requirements for general food as required for a toddler formula,” stated Dr. Fabiana Bar-Yoseph, Else’s Director of Clinical Development, Regulatory and Scientific Affairs. She added, “This regulatory validation marks a significant step as we look to bring a nutritious, plant-based toddler formula to the U.S. market.”
Else Nutrition’s 100% plant-based toddler formula is set to launch in the U.S. market in the second quarter of 2020.
PR From 12/10/2019
Else Nutrition Upgraded to Trade on the OTCQB Market
December 10, 2019 – Vancouver, BC – Else Nutrition Holdings Inc. (“Else Nutrition” or the “Company”) (TSXV: BABY) (OTCQB: BABYF) is pleased to announce that its common shares have been approved for trading on the OTCQB Market (“OTCQB”) under the symbol “BABYF” effective as of the open of trading today, December 10, 2019.
The OTCQB is a venture market operated by OTC Markets Group and designed for early-stage and developing U.S. and international companies. To be eligible, companies must be current in their reporting and undergo an annual verification and
About Else Nutrition Holdings Inc.
Else Nutrition is a mission-driven company focused on revolutionizing infant and toddler nutrition through its 100% plant-based and non-soy alternative to dairy-based baby formula. Winner of the “2017 Best Health and Diet Solutions” award at the Global Food Innovation Summit in Milan, Else’s innovative toddler formula will be launching in the United States in 2020. For more information, visit: elsenutrition.com.
About The Sawtooth Group
The Sawtooth Group is a full-service creative marketing agency that gets brand in shape. Sawtooth leverages food and fitness and health and wellness expertise to help create fit brands through brand strategy, e-commerce, social media and digital campaigns, packaging and material design and more. They are powered by I-Factor, their proprietary data insights and social listening tool. Sawtooth also leverages their state-of-the-art in-house studio kitchen to create high-quality and irresistible content on behalf of their clients. Founded in 1988, Sawtooth is located in Red Bank, NJ and is a Certified Women’s Business Enterprise. Check out Sawtooth on their website, Instagram and Facebook.
For more information, contact:
Chelsie Hodge, Director of Corporate Relations ELSE Nutrition Holdings Inc. E: chelsieh@elsenutrition.com P: (604)360-2977
Hamutal Yitzhak, CEO, Co-Founder & Director ELSE Nutrition Holdings Inc. E: hamutaly@elsenutrition.com P: +972(0)52-447-9931
TSX Venture Exchange
Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Caution Regarding Forward-Looking Statements
This press release contains statements that, to the extent they are not recitations of historical fact, constitute “forward-looking statements” within the meaning of applicable securities legislation. Forward-looking statements are typically identified by words such as “will”, “plan”, “hope to”, “intend” or similar expressions. Forward-looking statements in this press release include, but are not limited to, statements with respect to: the Company’s commercialization of its products and expected timing, expected go-to-market strategy (including marketing, proposed markets, sales, customer growth and market position), and industry conditions.
Such forward-looking statements reflect current estimates, beliefs and assumptions, which are based on management’s perception of historical trends, current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. No assurance can be given that the foregoing will prove to be correct.
Forward-looking statements made in this press release assume, among others, the successful completion of Else’s proposed scale-up for its products, and such statements are intended to apply only to the infant formula market for ages 12 months and above, and having all necessary regulatory approval as required by each target market.
Numerous risks and uncertainties could cause the Company’s actual results to differ materially from the estimates, beliefs and assumptions expressed or implied in the forward-looking statements, including, but not limited to: consumer demand for the Company’s products, whether the Company’s current and future products achieve commercialization, uncertainty regarding material changes in laws and regulations, retention of key personnel, the Company’s ability to expand into global markets and competitive developments.
The foregoing list of factors is not exhaustive, and other risks and uncertainties not presently known, or believed to be material, to management Additional information and other factors that could affect the operations or financial results of the Company are set out in the Company's Filing Statement dated May 14, 2019 under the heading “Risk Factors” and may be accessed through the SEDAR website (www.sedar.com).
Readers are cautioned not to place undue reliance on any forward-looking statements, which reflect management’s expectations only as of the date of this press release. The Company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
BABYF - Else Nutrition
This is an Israeli based company that is coming to market in Q2 2020 with the world’s first plant-based toddler and infant formula. Currently, baby formula is either dairy or soy based. Something like 40% of kids that are allergic to dairy are also allergic to soy. It seems these days that vegan / plant based is the new Atkins. This company may have carved out a nice niche for itself.
My last call was VBIV at .87, it’s now around $1.30. BABYF will have a crazy run as this quarter comes to an end.
$ITRK & $LTHO Both huge updates today!
ITRK released news confirming the r/m w/ Loop Media is on track and finalizing signatures will be done by Friday!
$LTHO CEO confirms that acquisition of the $5,000,000 Hemp company is on track to close on Jan. 15th. He still won't comment on Pure Hemp Collective but still praises them and did not deny they are the target acquisition!
Plus the momo on countless other tickers...! Get ready for OTC Season!
HAPPY NEW YEAR!!!!
$HYSR Hyper Solar Fuel Cells BIG GREEN CANDLES ON THE CHART HYSR
$LTHO Must Read DD package! Massive gain potential!
Confirmed share structure, per CEO, as of November 21st 2019
A/S 100 million
O/S 5.732 million
Float 350K
Quote from May 2019 newsletter:
Slow day, entire OTC's only traded about 2.7b shares so far and top 10 volume movers of which 9 of those are trip 0's, account for about 50% of that volume....
Happy Holidays all!
Thanks, I need to call the CEO again, see what's going on... only 350k float... CEO comes through and it could fly
iBox typo - should be "CBD"
"certified
for hemp production of CDB Certified Hemp (12-15% CDB Oil)"
Looks interesting at first glance... rolling in a company with $5M sales into a shell with $1M market cap... I'm going to do some reading.
Cheers,
SLam
$ITRK, $UBID, $OPTI, $LTHO, $SBES, $RMSL, $APHD all in for MASSIVE gains!
Three new hot plays... I wouldn't want to be w/o shares of any of them...
First $UBID... nice accumulation range right now but don't be fooled... once updates hit it's looking at .025-.06 easy... current pps .005....
Next $LTHO... updates are coming... been 2 years in the works CEO wants to make sure everything is correct before unleashing this beast... current pps .3395, target... multiple dollars... 350k shares float
The big one $ICTV... Today announced a multi billion , yes billion dollar merger with NoNo, a huge household name doing billions in revenues... current pps, .0165... targets being talked about are .05-.20 short term, multiple dollars long...
Good luck all!
So do I. Nice 8-k... should see interest grow as the DD checks out!
I think we have something at nsrs
$LTHO TOP PICK, GOING FOR DOLLARS Updated the ibox
https://investorshub.advfn.com/Sobeks-Stock-Forum-32420/
They're a little sloppy but it's the real deal, I been in touch w/ the ceo a couple times, he's excited, says the merger co. is too... Dream on the ltho board's been posting the dd... check his posts..
Also might want to check out CLWD, it's on fire today
Wow, that sounds good. Reading up on it now
Cool, BUDZ ran to over $10, LTHO info on the ltho board, it has a 350k share float, I already own about 15% of it and a few others about the same, holding for updates which should be hitting sometime between now and next week
Awesome, I’ll check it out, thanks.
Cool lol! I took the first few months of the year off, was nice, did a lot of traveling through the states... I'll check out acst, so far I like the volume... my next pick is ltho, some real potential there, ceo picks up the phone, it reminds me of BUDZ when it was under a buck
Haha. I definitely took some time off, now I’m back at it. I’m doing DD on another one in the health care sector (ACST).
So you back to trading? I thought you made a million on OCWP and retired.
Very nice, congrats
Nice, thanks. I'm doing real good, last 6 months or so months been very rewarding.
I’ve been well, thanks. I stumbled upon VBIV and I knew you’d see its potential, so I thought I’d share. Hope all is well.
VBIV definitely looks interesting! Good to see you post again! How you been?
VBIV (NASDAQ .86)
VBI Vaccines is a Massachusetts-based biotech company that has a hepatitis B vaccine that’s already approved, and selling in fifteen countries right now. It’s got a very large safety database (something we’ll discuss in a bit more detail shortly) and it’s designed to overcome the limitations of the currently available SOC vaccines. At a glance, then, it seems to not only have the potential to meet the unmet need (and in turn, the $700 million market opportunity) but also to represent a more attractive risk-reward profile than a Dyanavax/Heplisav exposure.
The asset in question is called Sci-B-Vac.
The list of countries in which Sci-B-Vac is already approved includes Hong Kong, Israel, Philippines, Vietnam and a large portion of West and Central Africa. To date, it has demonstrated safety and efficacy in over 300,000 patients, and VBI has a database of safety figures in hand that spans 5,000 doses.
The vaccine is created using hamster cells, which enables Sci-B-Vac to mimic the virus to which it’s designed to induce an immune response far more closely than so-called second generation vaccines, which use yeast cells to ‘package’ antigens. For reference, Heplisav-B uses yeast cells, but is able to reduce the dosing regimen when compared to the SOCs in the sector because it uses what’s called immunostimulatory sequences (ISS) as an adjuvant, instead of the alum adjuvant that things like Engerix (an example of one of the most widely used SOCs) employ.
The employing of hamster cells as packaging for the antigens, as well as Sci-B-Vac’s mimicking of all three surface antigens of the hepatitis B virus (the S antigen and the pre-S1 and pre-S2 surface antigens), results in an increase in immunogenicity without the necessity for an alternate adjuvant.
This is a key point, as it allows for a maintaining of the safety profile of the alum type vaccines, but an increased elicited response.
To put this another way, with Heplisav-B, Dynavax has taken second generation vaccines and added an adjuvant to allow for reduced dosage. In contrast, with Sci-B-Vac, VBI has completely reengineered the vaccine to allow for higher immunogenicity, which reduces the amount of the vaccine needed. In doing this, it’s reduced the necessary dosage, and overcome the dosing issue that we outlined above as serving to underpin the large unmet need in the space.
That’s not all.
VBI’s vaccine has also demonstrated an equally effective immunogenicity across all patient types – young, old, healthy, and (very importantly) immunosuppressed patients such as diabetes sufferers. There’s a real problem right now with current vaccine options not inducing immunogenicity in diabetes sufferers (and Heplisav-B is included in this group), and Sci-B-Vac seems to solve this problem.
So what’s the development pathway like?
The company is pushing right now to add the US and Europe to its list of approved regions. These are the two big-ticket markets, and approval in both could amount to more than $1 billion in revenue potential, above and beyond Dynavax’s $700 million Heplisav-B US potential. The European pathway is slightly ahead of that of the US, with the company having announced back in February that the CHMP (a department of the EMA) has expressed its support of VBI’s proposed plan to proceed to the Phase III clinical studies of Sci-B-Vac, and that the product information, as well as data from ongoing studies, supports the Phase III clinical studies and VBI’s planned filing of a market authorization application (MAA) for the vaccine. A pivotal study should kick off during the third quarter of this year, and this presents us with a potential 2018 approval in Europe.
According to most recent communication from management, the US approval program is running parallel to that of the European program, which suggests we should see a pivotal initiated in the US this year also, again serving up the potential for approval in 2018.
There’s also a considerable amount of institutional interest in the company. Arch Ventures, headed up by Robert Nelson, and Perceptive Advisors, the top performing sub $1 billion hedge fund of 2015, headed up by biotech guru Joseph Edelman, both hold large stakes in VBI.
Through Opko Health Inc. (NASDAQ:OPK), billionaire biotech entrepreneur Dr. Phillip Frost also holds a large, and growing, stake in the company.
The takeaway here is that VBI is likely around eighteen months behind Dynavax in terms of getting a hepatitis B vaccine on the market in the US and Europe, but given the information available right now, it looks as though VBI’s Sci-B-Vac has a far higher chance of getting a regulatory green light. Sci-B-Vac also looks superior to Heplisav-B, especially in the immunosuppressed patient population, giving the drug a higher peak sales potential than that of its Dynavax made counterpart.
$LTHO $NILA Nilam Resources finally came through today! 248%, keep it on watch for updates and filings. It's a toss up between a weed or mining r/m.... I think...
Killed it last couple days with FLCX and KWBT, both ran to the teens. Keeping em both on watch, they should trade actively, APHD was a good one when it popped over .002 on news...
GMEV, ACNV, and now NILA... all multi 100%'s, some of my biggest gainers all year... ENGA was a good one, too bad the CEO is a turd
AABB, who knows, has all the makings of a multi penny runner but it's just a turd right now... lack of trader group interest imo
PLFF... still trying to figure this one out, real light floater, hardly ever traded in the history of it, now volume slowly picking up... if something comes in here it could pop hard, .50ish... maybe hit a buck real quick... it's that light
LTHO Pay attention to this one. This should be the next mega mover.
The CEO's phone is on the LTHO iHub page, great guy, very knowledgeable, call if you can.
They're hopefully finalizing r/m negotiations w/ a $3+ million a year hemp retailer/manufacturer and have 2 more planned after that. Their license is active and they have the merger vehicle license active as well at the CO SOS.
It's like 2 years in the making and it's close, very close. They remind me of BUDZ, look at their history lol, sloppy just like LTHO but,,,, look at BUDZ now
LTHO Very light float, 350k, 5.7m o/s, most restricted, great entry points now, check the charts
Have a great long w/e
Have another winner here, (guilty of not posting here enough) but $LTHO is rocketing and should see .75-$1 next week and continue to climb from there, some solid DD on the LTHO board
That's fine, thanks for getting back. The L2 really lightened up, CSTI moved back way above a penny, I gat the patience, especially for a light floater like GMEV.
I wish I had more info for you and me ,I think it will be okay.Just remember, being quiet can be a good thing also,so lets go with that.I think before the year ends we"ll know.
$ACNV Don't get confused, Covalent Collective's case with the SEC is closed BUT... the SEC vs Accelera Innovations, Inc. case is still open! ACNV has/is getting sued by several shareholders in different states and the SEC.
Accelera has a $60m deficit, $2.5 million in liabilities including toxic debt, lots of shares issued for conversion, and they may need to carry the $7.5 million Thompson stole from investors as a debt...
Also no one has verified that tweet this am, no info on NVSOS is found on the site... just the tweet of what could be a forged pic showing names and address with no company name... but thanks to that, all the diluting market makers have shown up, dilution in quantity happening now.
Foreseeing only a BK can clean up this ticker... if anyone even wants it imo
Covalent Collective
https://www.courtlistener.com/docket/15723066/united-states-securities-and-exchange-commission-v-covalent-collective/
Accelera Innovations, Inc.
https://www.courtlistener.com/docket/6175286/us-securities-and-exchange-commission-v-accelera-innovations-inc/
$ACNV Running, there are several possibilities, waiting on updates.
$ENGA still holding 200% gains, accumulation is climbing, watch for breakout
$ARTR Massive upside potential, custodian case I believe 11/19. Very possible this is a done deal case, VP Ken Dehon already confirmed on twitter not with them anymore which speculates he already retired his shares.... thinking custodian attorney played match maker, ARTR management on board, and new company jumped the gun with twitter account
$GMEV super light floater just hanging around and waiting to get noticed
$NILA should be next, been sitting in the .002 range for too long plus it's been a long while since new CEO took over, should see updates soon imo
Two new really low floaters popped up today that have my attention, like very low floats @ a very nice pps
$OMMH pps .0041 Only 9.8m shares o/s. the highest volume day in 5 years was only 580k, so the float has to be way smaller, like maybe a couple million at most!
$TAER closed at .01, Only a 2 million share float highest day volume was 1.1 million around the first of the year but volume is picking up again, crack a milly in volume and who knows how high it can go!
$FTXP Running up now... should do good, less than 8 million shares floating
$ARTR Added a few, strong buys, strong bids, new 52wk high on heavy volume.
O/S is kind of heavy but there's very little debt and no toxic notes, this could be a r/m in the works...
$BBUCQ A monster waiting to wake up, co. working behind the scene to bring it back, just a matter of time, only 300k share float
$ENGA Ready for next level up imo. No sells in over a week, holding that .03 pps, 1.239 million float, active FL Business license, VCORP is the registered agent, s/s updated regularly, min debt, perfect candidate for a healthy r/m, active shell status on OTC profile page.
Followers
|
6
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
257
|
Created
|
08/02/17
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |